A leading compounding pharmacy specializing in Mold Toxicity, CIRS, Biotoxin Illness, Lyme Disease, Sinus and Allergy/ENT, Dermatology and Aesthetics.

Call Us Today 805-427-9053
Toll Free 855-427-9053
Fax Number 805-233-3933

Dr. Brewer’s Protocol

Dr. Brewer’s Protocol

Brewer’s Protocol is a multi-step biofilm-focused treatment for mycotoxins involving the use of a topical antifungal and a chelating agent. Dr. Joseph Brewer is an infectious disease specialist in private practice from Kansas City, Missouri. Dr. Brewer has a special interest in biotoxin illnesses/mold toxicity, Fibromyalgia, Chronic Fatigue Syndrome (CFS), Lyme Disease, and HIV/AIDS and has published ground-breaking papers like “Detection of mycotoxins in patients with Chronic Fatigue Syndrome” and Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?”. Dr. Brewer and his colleagues have made important discoveries in the treatment protocols of mold-exposed patients. Dr. Brewer’s publications have exposed an important link between mold exposure and chronic illnesses such as chronic fatigue syndrome (CFS) and fibromyalgia. [58] Furthermore, he has shown that the sinus area is a major internal reservoir that harbors mold in biofilm communities that generate mycotoxins internally.[59] Biofilm provides considerable protection for fungi, allowing them to chronically persist within the sinuses.[60] Recognizing this new information has enabled us to improve our treatment for mold toxicity and biotoxin illness.
Dr. Brewer’s research concludes that an effective protocol for mold-exposed patients must target fungal biofilm in the sinuses. [61] This includes the use of a chelating agent, such as EDTA, to disrupt biofilm as well as intranasal antifungal therapy with antifungal agents like Amphotericin B or Nystatin.[62] In addition, Bactroban (mupirocin) is often recommended to be used alongside the antifungal and chelating agent to aid in biofilm disruption. [63]Topical antibiotics have been widely used in the treatment of biofilm due to their easy administration and minimal systemic adverse effects.[64] In a clinical trial on the efficacy of topical Bactroban (mupirocin) treatment in the sinuses of chronic sinusitis (CRS) patients, it was concluded that mupirocin could be useful in eliminating Staphylococcus aureus (S. aureus) biofilms present on the sinus mucosa of CRS patients and offer an additional treatment method for patients with recurring sinusitis.[65]

At Forte Rx Compounding Pharmacy, we offer the complete Brewer’s protocol which includes the Rhino Clear Atomizer, EDTA solution, antifungals Amphotericin B solution and Nystatin as well as Bactroban (mupirocin) solution.

Relevant Studies
Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013). Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?. Toxins, 6(1), 66–80. https://doi.org/10.3390/toxins6010066

Brewer, J. H., Thrasher, J. D., Straus, D. C., Madison, R. A., & Hooper, D. (2013). Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins, 5(4), 605–617. https://doi.org/10.3390/toxins5040605

Brewer, J. H., Hooper, D., & Muralidhar, S. (2015). Intranasal antifungal therapy in patients with chronic illness associated with mold and mycotoxins: An observational analysis. Global Journal of Medical Research, 15, 29-33.

Please contact our clinical department today at (805) 427-9053 and ask to speak with one of our expert chronic inflammatory response syndrome (CIRS), mold/biotoxin illness, sinus, and Lyme Disease clinical pharmacists about Dr. Brewer’s Protocol.

[58]  Brewer, J. H., Thrasher, J. D., Straus, D. C., Madison, R. A., & Hooper, D. (2013). Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins, 5(4), 605–617. https://doi.org/10.3390/toxins5040605

[59] Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013). Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?. Toxins, 6(1), 66–80. https://doi.org/10.3390/toxins6010066

[60] Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013).https://doi.org/10.3390/toxins6010066

[61] Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013).https://doi.org/10.3390/toxins6010066

[62] Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013). https://doi.org/10.3390/toxins6010066

[63] Brewer, J. H., Hooper, D., & Muralidhar, S. (2015). Intranasal antifungal therapy in patients with chronic illness associated with mold and mycotoxins: An observational analysis. Global Journal of Medical Research, 15, 29-33.

[64] Goh, Y. H., & Goode, R. L. (2000). State of the Art Review: Current Status of topical nasal antimicrobial agents. The Laryngoscope, 110(6), 875–880. https://doi.org/10.1097/00005537-200006000-00001

[65] Ha KR, Psaltis AJ, Butcher AR, Wormald PJ, Tan LW. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118(3):535-40. doi: 10.1097/MLG.0b013e31815bf2e3. PMID: 18090864.